BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12721246)

  • 1. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.
    Thomas CT; Bradshaw PT; Pollock BH; Montie JE; Taylor JM; Thames HD; McLaughlin PW; DeBiose DA; Hussey DH; Wahl RL
    J Clin Oncol; 2003 May; 21(9):1715-21. PubMed ID: 12721246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
    Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
    Kahn D; Williams RD; Haseman MK; Reed NL; Miller SJ; Gerstbrein J
    J Clin Oncol; 1998 Jan; 16(1):284-9. PubMed ID: 9440754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.
    ProaƱo JM; Sodee DB; Resnick MI; Einstein DB
    J Urol; 2006 May; 175(5):1668-72. PubMed ID: 16600726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
    Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
    Wilkinson S; Chodak G
    J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capromab Pendetide imaging of prostate cancer.
    Haseman MK; Rosenthal SA; Polascik TJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.
    Sharma V; Nehra A; Colicchia M; Westerman ME; Kawashima A; Froemming AT; Kwon ED; Mynderse LA; Karnes RJ
    Eur Urol; 2018 Jun; 73(6):879-887. PubMed ID: 29195777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
    BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
    Kahn D; Austin JC; Maguire RT; Miller SJ; Gerstbrein J; Williams RD
    Cancer Biother Radiopharm; 1999 Apr; 14(2):99-111. PubMed ID: 10850293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?
    Goldstein J; Even-Sapir E; Ben-Haim S; Saad A; Spieler B; Davidson T; Berger R; Weiss I; Appel S; Lawrence YR; Symon Z
    Am J Clin Oncol; 2017 Jun; 40(3):256-259. PubMed ID: 25319322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
    Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J
    Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy.
    Neuhof D; Hentschel T; Bischof M; Sroka-Perez G; Hohenfellner M; Debus J
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1411-7. PubMed ID: 17275204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy.
    Patel R; Lepor H; Thiel RP; Taneja SS
    Urology; 2005 May; 65(5):942-6. PubMed ID: 15882728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
    Kahn D; Williams RD; Manyak MJ; Haseman MK; Seldin DW; Libertino JA; Maguire RT
    J Urol; 1998 Jun; 159(6):2041-6; discussion 2046-7. PubMed ID: 9598514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.